Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance
Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance
Becton, Dickinson and (NYSE:BDX – Get Rating) updated its FY23 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $12.07 to $12.32 for the period, compared to the consensus estimate of $11.97. Becton, Dickinson and also updated its FY 2023 guidance to $12.07-$12.32 EPS.
週四，Becton、Dickinson和(NYSE：BDX-GET Rating)更新了其23財年收益指引。該公司提供了12.07美元至12.32美元的每股收益指引，而市場普遍預期為11.97美元。該公司還將其2023財年每股收益指引更新為12.07-12.32美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several equities analysts recently commented on the stock. Morgan Stanley increased their price objective on shares of Becton, Dickinson and from $290.00 to $295.00 and gave the company an overweight rating in a research note on Friday. William Blair reaffirmed an outperform rating on shares of Becton, Dickinson and in a research note on Friday, November 11th. The Goldman Sachs Group dropped their price target on shares of Becton, Dickinson and from $319.00 to $272.00 and set a buy rating for the company in a research note on Wednesday, November 23rd. Evercore ISI dropped their price target on shares of Becton, Dickinson and to $270.00 in a research note on Wednesday, November 16th. Finally, Cowen dropped their price target on shares of Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $275.64.
幾位股票分析師最近對該股發表了評論。摩根士丹利在週五的一份研究報告中將貝頓、迪金森和貝克漢姆的股票目標價從290.00美元上調至295.00美元，並給出了該公司的增持評級。威廉·布萊爾在11月11日星期五的一份研究報告中重申了對Becton，Dickinson和的股票的強於大盤的評級。11月23日，高盛夫婦在一份研究報告中將貝頓、狄金森的目標股價從319.00美元下調至272.00美元，併為該公司設定了買入評級。11月16日，Evercore ISI在一份研究報告中下調了他們對Becton，Dickinson股票的目標價至270.00美元。最後，考恩在11月16日星期三的一份研究報告中將他們對Becton，Dickinson的股票目標價下調至255.00美元。四名研究分析師對該股的評級為持有，五名分析師對該公司的評級為買入。根據MarketBeat的數據，該公司目前的平均評級為中等買入，共識目標價為275.64美元。
Becton, Dickinson and Stock Down 1.1 %
Becton，Dickinson和股價下跌1.1%
NYSE:BDX traded down $2.63 during trading hours on Friday, reaching $245.84. The company had a trading volume of 2,117,712 shares, compared to its average volume of 1,236,927. The company has a quick ratio of 0.63, a current ratio of 1.04 and a debt-to-equity ratio of 0.55. The firm has a market cap of $69.88 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 2.23 and a beta of 0.54. The business's 50-day simple moving average is $251.52 and its two-hundred day simple moving average is $244.40. Becton, Dickinson and has a twelve month low of $215.90 and a twelve month high of $280.62.
紐約證券交易所：BDX在週五的交易時段下跌2.63美元，至245.84美元。該公司的成交量為2,117,712股，而其平均成交量為1,236,927股。該公司的速動比率為0.63，流動比率為1.04，債務權益比率為0.55。該公司市值為698.8億美元，市盈率為41.81倍，市盈率為2.23倍，貝塔係數為0.54。該業務的50日簡單移動均線切入位在251.52美元，200日簡單移動均線切入位在244.40美元。貝頓，迪金森，並有12個月低點215.90美元和12個月高點280.62美元。
Becton, Dickinson and Announces Dividend
Becton，Dickinson和宣佈分紅
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date of this dividend is Thursday, March 9th. Becton, Dickinson and's dividend payout ratio (DPR) is 61.90%.
該公司最近還披露了季度股息，將於3月31日(星期五)支付。3月10日(星期五)登記在冊的股東將獲得0.91美元的股息。這意味着年化股息為3.64美元，股息收益率為1.48%。本次股息除息日期為3月9日(星期四)。Becton，Dickinson and的股息支付率(DPR)為61.90%。
Institutional Inflows and Outflows
機構資金流入和流出
A number of large investors have recently made changes to their positions in the company. Zions Bancorporation N.A. lifted its position in shares of Becton, Dickinson and by 13.0% during the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 58 shares in the last quarter. Evergreen Capital Management LLC raised its position in Becton, Dickinson and by 0.6% in the first quarter. Evergreen Capital Management LLC now owns 12,238 shares of the medical instruments supplier's stock worth $3,255,000 after acquiring an additional 67 shares during the period. Global Wealth Management Investment Advisory Inc. raised its position in Becton, Dickinson and by 3.1% in the first quarter. Global Wealth Management Investment Advisory Inc. now owns 2,313 shares of the medical instruments supplier's stock worth $615,000 after acquiring an additional 69 shares during the period. Brighton Jones LLC raised its position in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier's stock worth $368,000 after acquiring an additional 112 shares during the period. Finally, Orion Portfolio Solutions LLC raised its position in Becton, Dickinson and by 10.7% in the first quarter. Orion Portfolio Solutions LLC now owns 1,181 shares of the medical instruments supplier's stock worth $314,000 after acquiring an additional 114 shares during the period. 87.08% of the stock is owned by institutional investors.
一些大型投資者最近對他們在該公司的頭寸進行了調整。Zion Bancorporation N.A.在第一季度將其在Becton，Dickinson的股票頭寸提高了13.0%。Zion Bancorporation N.A.在上個季度又購買了58股後，現在擁有這家醫療器械供應商504股股票，價值13.4萬美元。Evergreen Capital Management LLC在第一季度將其在Becton，Dickinson的頭寸提高了0.6%。Evergreen Capital Management LLC在此期間額外收購了67股，現在擁有這家醫療器械供應商12,238股股票，價值3,255,000美元。Global Wealth Management Investment Consulting Inc.在第一季度將其在Becton，Dickinson的持倉提高了3.1%。Global Wealth Management Investment Consulting Inc.現在持有這家醫療器械供應商的2,313股股票，價值61.5萬美元，在此期間又購買了69股。Bright ton Jones LLC在第一季度將其在Becton，Dickinson的頭寸提高了8.8%。Bright ton Jones LLC在此期間增持了112股，目前持有這家醫療器械供應商1,383股股票，價值36.8萬美元。最後，Orion Portfolio Solutions LLC在第一季度將其在Becton，Dickinson的頭寸提高了10.7%。Orion Portfolio Solutions LLC在此期間額外收購了114股，現在擁有這家醫療器械供應商價值314,000美元的股票1,181股。87.08%的股份由機構投資者持有。
Becton, Dickinson and Company Profile
貝頓、狄金森和公司簡介
(Get Rating)
(獲取評級)
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
Becton，Dickinson&Co從事醫療用品、設備、實驗室設備和診斷產品的開發、製造和銷售。它通過以下部門開展業務：BD醫療、BD生命科學和BD Intervative。BD醫療部門生產醫療技術和設備，用於幫助改善醫療保健服務。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免費獲取StockNews.com關於Becton、Dickinson和(BDX)的研究報告
- 細價股值得嗎？你應該投資細價股嗎？
- Zimmer Biomet盈利節節攀升，增長可能被計入價格
- 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
- 內部人士和機構收購金剛狼全球
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.
接受Becton Dickinson和Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Becton Dickinson和相關公司的最新新聞和分析師評級的每日簡要摘要。